catalyst · primary record
Cadisegliatin 800 mg QD + Cadisegliatin 800 mg BID + Placebo
Phase readout · 2027-04-01 · Diabetes Mellitus, Type 1
| Company | vTv Therapeutics |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P3 primary completion · NCT06334133 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:55.887Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: vTv Therapeutics:Cadisegliatin 800 mg QD + Cadisegliatin 800 mg BID + Placebo:2027-04-01:P3 primary completion · NCT06334133
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.